Table 3C.
Characteristics of the three eligible studies on cattle included in the meta-analysis for estimating seroprevalence of Toxoplasma gondii in the Nordic-Baltic region.
| Authors | Year of publication | Country | Study period | Sample type | Serological method | Sed | Spe | Total no. of cattle ≤1 year of age (no. of seropositives) | Total no. of cattle >1 year of age (no. of seropositives) | Total no. of cattle of unknown age (no. of seropositives) | Apparent seroprevalence (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Eglīte and Keidans, 2000 | 2000 | Latvia | 1993–1998 | Serum | CFa | n.r | n.r | n.r | n.r | 254 (2) | 0.8 |
| Allén, 2016 | 2016 | Finland | 2013–2014 | Meat juice | ELISAb | n.r | n.r | 0 | 185 (15) | 15 (0) | 7.5 |
| Jokelainen et al., 2017 | 2017 | Estonia | 2012–2013 | Serum | DATc | n.r. | n.r. | n.r | 3679 (707) | 312 (36) | 18.6 |
n.r. = not reported. a = Unspecified commercial complement fixation test (CF). b = Commercial ELISA, ID Screen Toxoplasmosis Indirect Multi-species IDvet Innovative Diagnostics Montpellier France) [Cut-off, S/P = 50%]. c = Commercial modified direct agglutination test (DAT), Toxo-Screen DA bioMérieux, Marcy-l'Étoile France [Cut-off, dilution of 1:100]. d = Se, sensitivity. e = Sp, specificity.